CCL2 and rheumatoid arthritis: PCSK9 antibodies have been shown to inhibit TNF-α and IL-1ß from macrophages, as well as MCP-1 from synoviocytes.275 Therefore, PCSK9-iTs may offer therapeutic benefits in RA, potentially more so in patients with high PCSK9 levels.